Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT05559008
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Eva Bonfill
- Target Recruit Count
- 24
- Registration Number
- NCT05527418
- Locations
- 🇪🇸
Eva Bonfill, Barcelona, Spain
Pilot Trial for Treatment of Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT05432518
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Lewis Lipsitz
- Target Recruit Count
- 12
- Registration Number
- NCT05422885
- Locations
- 🇺🇸
Hebrew Senior Life, Boston, Massachusetts, United States
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
- Conditions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1484
- Registration Number
- NCT05286528
- Locations
- 🇭🇺
Pfizer, Budapest, Hungary
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT05198843
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Conditions
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: Erwinia asparaginaseDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 30
- Registration Number
- NCT05042531
- Locations
- 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2021-10-01
- Target Recruit Count
- 80
- Registration Number
- NCT05024357
- Locations
- 🇨🇳
First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT05007873
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.